ARCHIVES

DCT Board Questions Funding, Direction Of IL-2/LAK Trials

This article is from The Cancer Letter archive.

Vol. 15 No. 10 | March 3, 1989

Download PDF Visit The Full Archive

Related Articles

MAP Says It Will Continue Operating With Private Funds

April 18, 1986

Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis

December 27, 2002

NCI 1980s Challenge: Matching Schientific Priorities With Resources, DeVita Says At Swearing-In

August 15, 1980

NCI’s Chabner Cautions Against 3-Hour Taxol Infusion, May Lower Response Rate

October 22, 1993

ACS Reorganization Plans, Policy Changes Discussed By Board

November 29, 1991

NCI’s Rosenberg Confirms 2002 Immunotherapy Results

April 29, 2005